{"protocolSection":{"identificationModule":{"nctId":"NCT02059785","orgStudyIdInfo":{"id":"CSPC-HA1301"},"organization":{"fullName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","class":"INDUSTRY"},"briefTitle":"Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke","officialTitle":"Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke---Randomized, Double-blind, Placebo-controlled, Multicenter Study"},"statusModule":{"statusVerifiedDate":"2015-10","overallStatus":"SUSPENDED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-06"},"primaryCompletionDateStruct":{"date":"2016-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2016-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2014-02-07","studyFirstSubmitQcDate":"2014-02-07","studyFirstPostDateStruct":{"date":"2014-02-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-06-16","lastUpdatePostDateStruct":{"date":"2016-06-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This research is a Randomized, double-blind, placebo-controlled, multicenter clinical study. Chinese subjects with Ischemic Stroke.","detailedDescription":"Subjects will randomly enter into one of two groups,the period of treatment is 14 days,follow-up to the 90th days."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["Pinocembrin for Injection","Placebo","mRS"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":216,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Pinocembrin for Injection","type":"EXPERIMENTAL","description":"40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day","interventionNames":["Drug: Pinocembrin for Injection"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","description":"60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day","interventionNames":["Drug: Pinocembrin for Injection"]}],"interventions":[{"type":"DRUG","name":"Pinocembrin for Injection","armGroupLabels":["Pinocembrin for Injection","placebo"],"otherNames":["DL0108"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To determination the proportion of subjects that 0-1 score of mRS after treatment 90 days","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"To compare treatment arms in terms of change from baseline to endpoint in NIHSS score.","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 35-75 hospitalized patients\n* Patients with acute stroke ≤24h\n* NIHSS score 6-20 at time of enrollment , the score ≥2 of item 5 and/or 6\n* For the first time or always without obvious sequelae of stroke disease(mRS≤1）\n* Informed consent\n\nExclusion Criteria:\n\n* The disease such as Acute intracerebral hemorrhage,tumor and encephalitis which cause similar symptoms\n* Patient with NIHSS level of consciousness score≥2 or dementia,or other patients who the investigator think that don't fit into the study\n* TIA\n* Symptoms of disease rapidly improving during the randomized\n* Severe hypertension(SBP \\> 200 mmHg or DBP \\>110 mmHg)\n* Inadequate liver function(AST or ALT greater than 2 times the upper limit of normal values);Renal impairment (Creatinine clearance \\<60ml/min）\n* Severe system or viscera organic disease\n* Have used other neuroprotectant or other experimental drugs\n* Patient who are unlikely to complete the study that due to a severe clinical condition\n* Pregnant or breast-feeding\n* Participation in a previous clinical study within 30 days\n* Meets all other exclusion criteria","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Wang Yong Jun, Ph.D","affiliation":"Beijing Tiantan Hospital affilliated to Capital Medical University","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Beijing Tiantan Hospital affilliated to Capital Medical University","city":"Beijing","state":"Beijing","zip":"100050","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M11600","name":"Mitral Valve Insufficiency","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}